Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Teva
US Department of Justice
Novartis
Julphar
Medtronic
Accenture
Farmers Insurance
Chinese Patent Office
Express Scripts

Generated: December 10, 2017

DrugPatentWatch Database Preview

Pfizer Company Profile

« Back to Dashboard

What is the competitive landscape for PFIZER, and what generic alternatives to PFIZER drugs are available?

PFIZER has one hundred and fifty-four approved drugs.

There are sixty-two US patents protecting PFIZER drugs and there have been two Paragraph IV challenges on PFIZER drugs in the past three years. There is one tentative approval on PFIZER drugs.

There are one thousand eight hundred and seventy patent family members on PFIZER drugs in seventy-nine countries and one hundred and fifty-six supplementary protection certificates in fourteen countries.

Summary for Pfizer

International Patents:1870
US Patents:62
Tradenames:121
Ingredients:107
NDAs:154
Drug Master File Entries: 3
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
PfizerGEODONziprasidone hydrochlorideCAPSULE;ORAL020825-004Feb 5, 2001ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
PfizerCARDURA XLdoxazosin mesylateTABLET, EXTENDED RELEASE;ORAL021269-002Feb 22, 2005RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
PfizerTOVIAZfesoterodine fumarateTABLET, EXTENDED RELEASE;ORAL022030-002Oct 31, 2008ABRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
PfizerTETRACYNtetracycline hydrochlorideINJECTABLE;INJECTION060096-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Pfizer IncCHANTIXvarenicline tartrateTABLET;ORAL021928-002May 10, 2006RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
PfizerJUNIOR STRENGTH ADVILibuprofenTABLET, CHEWABLE;ORAL020944-002Dec 18, 1998OTCNoNo► Subscribe► Subscribe► Subscribe► Subscribe
PfizerATARAXhydroxyzine hydrochlorideTABLET;ORAL010392-006Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Pfizer PharmsNEURONTINgabapentinTABLET;ORAL020882-002Oct 9, 1998ABRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Pfizer IncTROXYCA ERnaltrexone hydrochloride; oxycodone hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL207621-001Aug 19, 2016DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Pfizer IncELLENCEepirubicin hydrochlorideINJECTABLE;INJECTION050778-002Sep 15, 1999APRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Pfizer

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
PfizerMINIPRESS XLprazosin hydrochlorideTABLET, EXTENDED RELEASE;ORAL019775-002Jan 29, 1992► Subscribe► Subscribe
PfizerGEODONziprasidone hydrochlorideCAPSULE;ORAL020825-004Feb 5, 2001► Subscribe► Subscribe
PfizerTROVANtrovafloxacin mesylateTABLET;ORAL020759-002Dec 18, 1997► Subscribe► Subscribe
PfizerEXUBERAinsulin recombinant humanPOWDER;INHALATION021868-002Jan 27, 2006► Subscribe► Subscribe
PfizerSONATAzaleplonCAPSULE;ORAL020859-002Aug 13, 1999► Subscribe► Subscribe
PfizerADVIL COLD AND SINUSibuprofen; pseudoephedrine hydrochlorideTABLET;ORAL019771-001Sep 19, 1989► Subscribe► Subscribe
Pfizer PharmsACCURETIChydrochlorothiazide; quinapril hydrochlorideTABLET;ORAL020125-001Dec 28, 1999► Subscribe► Subscribe
PfizerCADUETamlodipine besylate; atorvastatin calciumTABLET;ORAL021540-005Jan 30, 2004► Subscribe► Subscribe
Pfizer PharmsACCUPRILquinapril hydrochlorideTABLET;ORAL019885-001Nov 19, 1991► Subscribe► Subscribe
Pfizer IrelandRELPAXeletriptan hydrobromideTABLET;ORAL021016-001Dec 26, 2002► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for PFIZER drugs

Drugname Dosage Strength Tradename Submissiondate
tofacitinibExtended-release Tablets11 mgXELJANZ XR11/7/2016
ibuprofen and diphenhydramine citrateCapsules200 mg/38 mgADVIL PM2/16/2016
dofetilideCapsules0.125 mg, 0.25 mg, and 0.5 mgTIKOSYN5/1/2014
fesoterodine fumarateExtended-release Tablets4 mg and 8 mgTOVIAZ10/31/2012
nitroglycerinSublingual Tablets0.6 mgNITROSTAT12/29/2011
azithromycinFor Injection500 mg/vialZITHROMAX6/17/2011
varenicline tartrateTablets0.5 mg and 1 mgCHANTIX5/10/2010
eletriptan hydrobromideTablets20 mg and 40 mgRELPAX3/29/2010
amlodipine besylate and atorvastatin calciumTablets2.5 mg/40 mgCADUET9/17/2009
amlodipine besylate and atorvastatin calciumTablets5 mg/80 mgCADUET4/7/2009
amlodipine besylate and atorvastatin calciumTablets5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 10 mg/10 mg, 10 mg/20 mg and 10 mg/80 mgCADUET12/29/2006
sertraline hydrochlorideTablets150 mg and 200 mgZOLOFT11/9/2005
nitroglycerinSublingual Tablets0.3 mg, 0.4 mg and 0.6 mgNITROSTAT10/19/2005
zaleplonCapsules5 mg and 10 mgSONATA6/21/2005
ziprasidone hydrochlorideCapsules20 mg, 40 mg, 60 mg and 80 mgGEODON2/7/2005
ibuprofen potassium and pseudoephedrine hydrochlorideCapsules200 mg/30 mgADVIL COLD AND SINUS12/27/2004
sildenafil citrateTablets25 mg and 50 mgVIAGRA11/19/2004
sildenafil citrateTablets100 mgVIAGRA10/25/2004
irinotecan hydrochlorideInjection20 mg/mL, 2 mL and 5 mL vialsCAMPTOSAR7/26/2004

Premature patent expirations for PFIZER

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

Non-Orange Book Patents for Pfizer

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,161,969Dry powder dispersing apparatus and methods for their use► Subscribe
6,589,560 Stable glassy state powder formulations► Subscribe
5,024,843 Oral hypoglycemic glipizide granulation► Subscribe
6,407,236 Adenosine A3 receptor modulators► Subscribe
7,138,141Dispersible macromolecule compositions and methods for their preparation and use► Subscribe
6,479,049 Methods and compositions for the dry powder formulation of interferons► Subscribe
7,432,370Chiral salt resolution► Subscribe
7,422,013Dry powder dispersing apparatus and methods for their use► Subscribe
8,062,667Modified release formulations containing drug-ion exchange resin complexes► Subscribe
5,847,151 Gaba and L-glutamic acid analogs for antiseizure treatment► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Pfizer Drugs

Country Document Number Estimated Expiration
Hungary229867► Subscribe
Brazil9406435► Subscribe
Poland316199► Subscribe
Spain2165857► Subscribe
South Korea100419037► Subscribe
Morocco21323► Subscribe
Morocco26851► Subscribe
Norway980207► Subscribe
New Zealand257212► Subscribe
Canada2274758► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Pfizer Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
70034Netherlands► SubscribePRODUCT NAME: ATORVASTATINUM,DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF VAN HET INWENDIGE DELTA-LACTON, IN HET BIJZONDER ATORVASTATINUM CALCICUM TRIHYDRICUM; NAT. REGISTRATION NO/DATE: RVG 21081 - RVG 21083 19970421; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107
90036-0Sweden► SubscribePRODUCT NAME: KOMBINATION AV INSULIN DEGLUDEK OCH INSULIN ASPART; REG. NO/DATE: EU/1/12/806/001 20130121
8Finland► Subscribe
C0008Belgium► SubscribePRODUCT NAME: FOSPHENYTOINUM DINATRICUM; REGISTRATION NO/DATE: 19 IS 102 F12 19980901; FIRST REGISTRATION: GB PL00019/1057 19980204
2017000014Germany► SubscribePRODUCT NAME: PALBOCICLIB, OPTIONAL IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, ESTERS, AMIDES ODER EINES PRODRUGS HIERVON; REGISTRATION NO/DATE: EU/1/16/1147 20161109
00596Netherlands► SubscribePRODUCT NAME: INSULINE DEGLUDEC; REGISTRATION NO/DATE: EU/1/12/807/001EU/1/12/807/004EU/1/12/807/005EU/1/12/807/007EU/1/12/807/008EU/1/12/807/009EU/1/12/807/012EU/1/12/807/013EU/1/12/807/015 2013210121
/2000Austria► SubscribePRODUCT NAME: INSULIN ASPART/PROTAMIN; NAT. REGISTRATION NO/DATE: EU/1/00/142/001-008 20000801; FIRST REGISTRATION: LI 55414-55416 20000623
0641330/01Switzerland► SubscribeFORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
C0021Belgium► SubscribePRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209
2107069/01Switzerland► SubscribePRODUCT NAME: INSULIN DEGLUDEC; REGISTRATION NO/DATE: SWISSMEDIC 62563 12.03.2013
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Mallinckrodt
Argus Health
Fish and Richardson
Express Scripts
Federal Trade Commission
McKinsey
Chubb
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot